Lilly plans to build four new pharmaceutical manufacturing sites in the U.S.

Eli Lilly (LLY) and Company announced at plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. This brings the company’s total U.S. capital expansion commitments to more than $50B since 2020. Three of the future U.S. sites announced will focus on manufacturing active pharmaceutical ingredients, reshoring critical capabilities of small molecule chemical synthesis and further strengthening Lilly’s supply chain. The fourth location will extend the company’s global parenteral manufacturing network for future injectable therapies. At these four new sites, Lilly expects to create more than 3,000 jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians. Additionally, the company anticipates that it could create nearly 10,000 construction jobs during the development of the sites. The company’s previous total domestic capital expansion commitments from 2020 to 2024 totaled $23B and represented in today’s $50B announcement, included: New sites in Research Triangle Park and Concord, North Carolina; New sites at the LEAP Innovation District in Lebanon, Indiana; Expansions and updates to several different manufacturing facilities in Indianapolis; Development of the new Lilly Medicine Foundry in Lebanon, Indiana; Acquisition and expansion of Lilly’s manufacturing site in Kenosha County, Wisconsin. The company is currently in negotiations with several states and welcomes additional interest by March 12, 2025. Lilly expects to announce all four future site locations in 2025 and anticipates facilities will begin making medicines for patients within five years.